These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 32680953)

  • 1. Shed it, and help-LAG3 cleavage drives conventional CD4
    Seidel L; Bengsch B
    Sci Immunol; 2020 Jul; 5(49):. PubMed ID: 32680953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resistance to PD1 blockade in the absence of metalloprotease-mediated LAG3 shedding.
    Andrews LP; Somasundaram A; Moskovitz JM; Szymczak-Workman AL; Liu C; Cillo AR; Lin H; Normolle DP; Moynihan KD; Taniuchi I; Irvine DJ; Kirkwood JM; Lipson EJ; Ferris RL; Bruno TC; Workman CJ; Vignali DAA
    Sci Immunol; 2020 Jul; 5(49):. PubMed ID: 32680952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
    Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
    Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LAGging behind no more: PD-1 has a new immunotherapy partner.
    Gunderson AJ
    Immunity; 2024 Oct; 57(10):2266-2268. PubMed ID: 39383843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Research Progress Concerning Dual Blockade of Lymphocyte-Activation Gene 3 and Programmed Death-1/Programmed Death-1 Ligand-1 Blockade in Cancer Immunotherapy: Preclinical and Clinical Evidence of This Potentially More Effective Immunotherapy Strategy.
    Qi Y; Chen L; Liu Q; Kong X; Fang Y; Wang J
    Front Immunol; 2020; 11():563258. PubMed ID: 33488573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential targeting of PI3Kδ and LAG3 as an effective anti-cancer approach.
    Lauder SN; Vanhaesebroeck B; Gallimore A
    Br J Cancer; 2021 Aug; 125(4):467-469. PubMed ID: 33824480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-LAG-3 boosts CD8 T cell effector function.
    Kureshi CT; Dougan M; Dougan SK
    Cell; 2024 Aug; 187(16):4144-4146. PubMed ID: 39121844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different Expression Characteristics of LAG3 and PD-1 in Sepsis and Their Synergistic Effect on T Cell Exhaustion: A New Strategy for Immune Checkpoint Blockade.
    Niu B; Zhou F; Su Y; Wang L; Xu Y; Yi Z; Wu Y; Du H; Ren G
    Front Immunol; 2019; 10():1888. PubMed ID: 31440257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual Blockade of PD-1 and LAG3 Immune Checkpoints Increases Dendritic Cell Vaccine Mediated T Cell Responses in Breast Cancer Model.
    Barshidi A; Karpisheh V; Noukabadi FK; Kiani FK; Mohammadi M; Afsharimanesh N; Ebrahimi F; Kiaie SH; Navashenaq JG; Hojjat-Farsangi M; Zolbanin NM; Mahmoodpoor A; Hassannia H; Nami S; Jalali P; Jafari R; Jadidi-Niaragh F
    Pharm Res; 2022 Aug; 39(8):1851-1866. PubMed ID: 35715669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategies to overcome resistance to PD-1 inhibitors.
    Gajewski TF
    Clin Adv Hematol Oncol; 2020 May; 18(5):270-272. PubMed ID: 32628654
    [No Abstract]   [Full Text] [Related]  

  • 11. PD-1/LAG-3 co-signaling profiling uncovers CBL ubiquitin ligases as key immunotherapy targets.
    Chocarro L; Blanco E; Fernandez-Rubio L; Garnica M; Zuazo M; Garcia MJ; Bocanegra A; Echaide M; Johnston C; Edwards CJ; Legg J; Pierce AJ; Arasanz H; Fernandez-Hinojal G; Vera R; Ausin K; Santamaria E; Fernandez-Irigoyen J; Kochan G; Escors D
    EMBO Mol Med; 2024 Aug; 16(8):1791-1816. PubMed ID: 39030301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target.
    Qian W; Zhao M; Wang R; Li H
    J Hematol Oncol; 2021 Sep; 14(1):147. PubMed ID: 34526102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LAG3 and PD1 Regulate CD8+ T Cell in Diffuse Large B-cell Lymphoma Patients.
    Liu Y; Guo X; Zhan L; Wang L; Wang X; Jiang M
    Comput Math Methods Med; 2021; 2021():4468140. PubMed ID: 34422089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-L1-Independent Mechanisms Control the Resistance of Melanoma to CD4
    Goding SR; Wilson KA; Rosinsky C; Antony PA
    J Immunol; 2018 May; 200(9):3304-3311. PubMed ID: 29602773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progress of lymphocyte activation gene 3 and programmed cell death protein 1 antibodies for cancer treatment: A review.
    Li YQ; Chen XM; Si GF; Yuan XM
    Biomol Biomed; 2024 Apr; 24(4):764-774. PubMed ID: 38581716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of primary and acquired resistance to PD-1/PD-L1 blockade and the emerging role of gut microbiome.
    Zou R; Wang Y; Ye F; Zhang X; Wang M; Cui S
    Clin Transl Oncol; 2021 Nov; 23(11):2237-2252. PubMed ID: 34002348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Poxvirus-Based Active Immunotherapy with PD-1 and LAG-3 Dual Immune Checkpoint Inhibition Overcomes Compensatory Immune Regulation, Yielding Complete Tumor Regression in Mice.
    Foy SP; Sennino B; dela Cruz T; Cote JJ; Gordon EJ; Kemp F; Xavier V; Franzusoff A; Rountree RB; Mandl SJ
    PLoS One; 2016; 11(2):e0150084. PubMed ID: 26910562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunologic Features of Patients With Advanced Hepatocellular Carcinoma Before and During Sorafenib or Anti-programmed Death-1/Programmed Death-L1 Treatment.
    Macek Jilkova Z; Aspord C; Kurma K; Granon A; Sengel C; Sturm N; Marche PN; Decaens T
    Clin Transl Gastroenterol; 2019 Jul; 10(7):e00058. PubMed ID: 31295151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The co-expression characteristics of LAG3 and PD-1 on the T cells of patients with breast cancer reveal a new therapeutic strategy.
    Du H; Yi Z; Wang L; Li Z; Niu B; Ren G
    Int Immunopharmacol; 2020 Jan; 78():106113. PubMed ID: 31841754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LAG3 (CD223) as a cancer immunotherapy target.
    Andrews LP; Marciscano AE; Drake CG; Vignali DA
    Immunol Rev; 2017 Mar; 276(1):80-96. PubMed ID: 28258692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.